Leifer BS, Doyle SK, Richters A, Evans HL, Koehler AN. An Array-Based Ligand Discovery Platform for Proteins With Short Half-Lives. Methods Enzymol. 2018;610:191-218. doi:10.1016/bs.mie.2018.09.019.
Singh G, Dahlin JL, Walters MA. Risk Management in Early Discovery Medicinal Chemistry. Methods Enzymol. 2018;610:1-25. doi:10.1016/bs.mie.2018.09.012.
Jordi J, Guggiana-Nilo D, Bolton AD, et al. High-throughput screening for selective appetite modulators: A multibehavioral and translational drug discovery strategy. Sci Adv. 2018;4(10):eaav1966. doi:10.1126/sciadv.aav1966.
Fang C, Lee KK, Nietupski R, et al. Discovery of heterocyclic replacements for the coumarin core of anti-tubercular FadD32 inhibitors. Bioorg Med Chem Lett. 2018;28(22):3529-3533. doi:10.1016/j.bmcl.2018.09.037.
Iyer KR, Camara K, Daniel-Ivad M, et al. An oxindole efflux inhibitor potentiates azoles and impairs virulence in the fungal pathogen Candida auris. Nat Commun. 2020;11(1):6429. doi:10.1038/s41467-020-20183-3.
Li YI, Wei L, Meinsohn M-C, et al. A screen of repurposed drugs identifies AMHR2/MISR2 agonists as potential contraceptives. Proc Natl Acad Sci U S A. 2022;119(15):e2122512119. doi:10.1073/pnas.2122512119.
Peng LF, Kim SS, Matchacheep S, et al. Identification of novel epoxide inhibitors of hepatitis C virus replication using a high-throughput screen. Antimicrob Agents Chemother. 2007;51(10):3756-9. doi:10.1128/AAC.00233-07.
Ng SY, Yoshida N, Christie AL, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9(1):2024. doi:10.1038/s41467-018-04356-9.
Perlstein EO, Ruderfer DM, Roberts DC, Schreiber SL, Kruglyak L. Genetic basis of individual differences in the response to small-molecule drugs in yeast. Nat Genet. 2007;39(4):496-502. doi:10.1038/ng1991.
Shaw AT, Winslow MM, Magendantz M, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci U S A. 2011;108(21):8773-8. doi:10.1073/pnas.1105941108.